Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunothe…

POPULAR TAGS

Gene therapy play Orchard raises 30.7 million

Written by LVS on in the category news with the tags , .


Orchard Therapeutics (London, U.K.) raised $30.7 million in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies for primary immune deficiencies, metabolic diseases and hematological disorders. The newco's lead program is a lentiviral gene therapy in the clinic to treat severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).

F-Prime Capital led the round. UCL Business plc also participated, as did the UCL Technology Fund, which University College London launched this year.

Orchard said it has development partnerships with five research institutions: UCL, the Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester, the University of California Los Angeles and Boston Children's Hospital.

The start-up said interim data from March showed the ADA-SCID gene therapy led to "significant immune reconstitution" and 100% survival among 32 patients treated at Great Ormond and UCLA.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is developing Strimvelis (GSK2696273), a gene therapy that delivers ADA via a retroviral vector for ex vivo hematopoietic stem cell therapy, to treat ADA-SCID in patients for whom no suitable stem cell donor is available. Last month, EMA's CHMP recommended Strimvelis' approval.

Article adapted from BioCentury.

Read more about: , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunothe…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation Turnstone GSK Itera Life Science Biowin UGent KU Leuven Flanders.bio Janssen V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.